Podcasts about DFS

Play Episode Listen Later Jun 27, 2025 89:58

Send us a textWELCOME TO THE NEWEST EPISODE OF THE DYNASTY DNA DEEP DIVE PODCAST ON THE DYNASTY DNA PODCASTING NETWORK!! This show will be releasing every Friday with the Host of The Dynasty DNA Podcast TJ Blake, Dynasty DNA Team Member Bob Helfert (AKA Big Bob) and Dynasty DNA team member Noah Hutchinson (AKA SLIM)! In this episode we breakdown the AFC as a Division ahead of the 2025 season! We talk things such as how Quinshon Judkins fair in his rookie season will! We also discuss could Ja'Marr Chase and Tee Higgins both finish as WR1's! Lastly, what's Kaleb Johnson's ceiling as a Dynasty asset? It's a great episode so tune in with us, have a few laughs, and let's get you on your way to dynasty championship in 2025 it all begins this offseason!Join The DNA Strand Crew on Discord Free to Join Just Click This Link!!https://discord.gg/rFAyWzn8Join the DNA Strand Crew on Twitterhttps://mobile.twitter.com/DynastyDNA_Subscribe to The Dynasty DNA YouTube Channel(9) Dynasty DNA Fantasy Football Podcast - YouTubeFollow The DNA Guys On TwitterTJ Blake https://twitter.com/TJBlakeDNABob Helfert Bob Helfert (@BigefatBob) / XNoah Hutchinson Noah Hutchinson (@12thmanfantasy1) / X

Dynasty Focus: Buy Low, Sell High & Anthony Davis vs. Cooper Flagg Trade Explored

spotify apple trade discord los angeles lakers google play nba draft dynasty app store anthony davis dfs explored cooper flagg buy low sell high

Play Episode Listen Later Jun 26, 2025 58:13

Join Rick Kamla and Dr. A on Fantasy NBA Today for a deep dive into dynasty fantasy basketball strategy that could shape the future of your team! We'll kick off with essential advice on mastering the buy-low and sell-high approach. Learn how to identify players who are currently undervalued but primed for a resurgence, and conversely, who to consider moving at their peak value to maximize your assets. We'll discuss key indicators and market trends to help you make these crucial long-term decisions. Then, we tackle the burning question on every dynasty manager's mind: Should you trade Anthony Davis for Cooper Flagg today? This is a true litmus test for your team's philosophy. We'll weigh: Anthony Davis's consistent elite production, his role on the Lakers, and long-term durability concerns. Cooper Flagg's unprecedented hype as the #1 pick of the 2025 NBA Draft, his "generational talent" ceiling, and the inherent uncertainty of any rookie prospect. This episode is packed with expert analysis to help you make informed decisions, whether you're contending for a championship now or meticulously building a future dynasty. Don't miss this critical discussion! Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS—perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips!

Innovations in GU Cancer Treatment at ASCO25

ASCO Daily News

Play Episode Listen Later Jun 26, 2025 29:46

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News. I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode. Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC. Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings. So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease. So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting. So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting. So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response. So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma. So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025. So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence. So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj. Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer. So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response. These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months. Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup. So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj. Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial. A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion. So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance. So, thank you, Jeanny, for joining me today and sharing your insights. And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:   Dr. Neeraj Agarwal    @neerajaiims    Dr. Jeanny Aragon-Ching  Follow ASCO on social media:      @ASCO on Twitter      ASCO on Bluesky  ASCO on Facebook      ASCO on LinkedIn      Disclosures: Dr. Neeraj Agarwal: Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas Dr. Jeanny Aragon-Ching:  Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono  Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,   Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

Austin Ekeler Interview: Will The NFL Go Run Heavy Again, What Players Think Of Fantasy Football, Listener Questions, And More (Episode 875 with Adam Levitan)

Play Episode Listen Later Jun 25, 2025 30:16

Former Los Angeles Chargers and current Washington Commanders Running Back Austin Ekeler joins Adam Levitan and the ETR Football podcast to answer a lot of the hottest questions around the NFL and Fantasy Football, as well as promote his 2025 Charity Fantasy Football League, where you can enter for the chance to win huge prizes like signed game-worn cleats, a championship ring and much more.For more information on the Austin Ekeler Charity Fantasy Football League and the Austin Ekeler Foundation, hit this link: https://charitydraft.com/austin-ekeler-fantasy-football-charity-league/⁠In this episode, we discuss:- How professional Running Backs respond to "Running Backs don't matter"? - How do players in the NFL see fantasy football?- Would Austin let his children play football?- Should you care about off-season depth charts?- What does he think of the NFL's swing back to favoring the running game?Timestamps:0:00 - Intro0:52 - Explaining The Run/Pass Swing4:32 - How NFL Players See Fantasy Football7:18 - Austin's Charity Fantasy Football League9:40 - Responding to “Running Backs don't matter”14:33 - How Injuries Are Shaping Football's Future16:26 - Thoughts On The Guardian Cap17:47 - How Much Off-Season Depth Charts Correlate To Game Time 20:06 - Establishing Guaranteed Contracts in The NFL21:56 - Listener QuestionsDownload the DraftKings Daily Fantasy app now to draft your $20 Best Ball lineup to play for a share of $15 million—and get a second ticket to play FREE for a share of $15 million. That's two chances to win big without ever setting your lineup again. Draft One, Get One—only on DraftKings. The Crown Is Yours. https://dkng.co/BestBallETRGambling Problem? Call 1-800-GAMBLER or 877-8-HOPENY/text HOPENY (467369) (NY). Help is available for problem gambling. Call ⁠(888) 789-7777⁠ or visit ⁠ccpg.org⁠ (CT). 18+ in most eligible states, but age varies by jurisdiction. Eligibility restrictions apply. Void where prohibited. One per customer. Enter the Best Ball $15M headliner contest by 9/4/25 to get one bonus entry. $20 entry fee required. Reward expires in thirty days. See terms at draftkings.com/nfl-best-ball. Sponsored by DK.Want ETR on your team this season? Our 2025 NFL Best Ball Product has you covered with:Real-Time RankingsResearch & Analysis ArticlesDraft Strategy ContentDraft LivestreamsDiscord CommunityQ&As with ETR TeamSubscribe now at https://establishtherun.com/subscribe/ DFS OPTIMIZER: Sign up for THE SOLVER for access to the software we think fantasy players need to win: https://thesolver.com/?ref=etrWE CAN HELP: Tired of attention-seeking hot takes? Get the highest-quality fantasy football analysis in your inbox, FREE: https://bit.ly/establishtherunSPORTSBOOK OFFERS: We've partnered with several major sportsbook outlets to help supply you with the best offers in the industry and ensure you're maximizing your bankroll from the start: https://establishtherun.com/offers/FOLLOW US: Check out our social media channels for FREE fantasy football & DFS videos, analysis, and more: https://linktr.ee/establishtherun

nfl ny players responding reward fantasy football void listener questions running backs draftkings gambler eligibility dk dfs get one hopeny austin ekeler best ball solver adam levitan crown is yours draftkings daily fantasy

Pacers, NBA Champion Thunder & Blockbuster Trades

Play Episode Listen Later Jun 25, 2025 69:03

Join Rick Kamla and Dr. A on Fantasy NBA Today for an electrifying episode covering the biggest storylines and fantasy impacts of the NBA offseason! We'll begin with a comprehensive analysis of the Indiana Pacers' thrilling 2024-25 season and the NBA Champion Oklahoma City Thunder's historic championship run. What were the key fantasy takeaways from their impressive campaigns, and how does winning a title reshape the Thunder's individual fantasy outlooks? Then, we dive headfirst into the latest blockbuster NBA trades that are shaking up the league! Rick and Doc provide immediate, in-depth fantasy impact analysis on: Kevin Durant's move to the Houston Rockets: How does this alter the fantasy landscape for KD and the Rockets' young core? Kristaps Porzingis traded to the Atlanta Hawks: What does this mean for KP's role and the Hawks' fantasy-relevant players? Jordan Poole's new chapter with the New Orleans Pelicans: How will his fantasy value change in a new system, especially with key players out? This episode is your ultimate guide to understanding the strategic offseason moves and their direct implications for your fantasy basketball draft. Don't miss this crucial breakdown of the champions, the contenders, and the immediate fantasy fallout from the latest NBA trades! Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS—perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips!

2025 Rocket Classic Live Chat - DFS, Betting, One & Done Advice | The Early Wedge

Play Episode Listen Later Jun 25, 2025 60:00

Let's answer your questions! Sia Nejad and Rick Gehman are here for any last minute Rocket Classic betting, DFS or One & Done advice. (0:00) Intro + the bulk of the strength of this field (5:00) Let's answer your questions! #SportsBetting #Gambling #Betting #RocketClassic #GolfBetting #OneandDone #GolfDFS #FantasySports #sianejad #mikemcclure #PGATour #Golf

tv spotify tiktok head apple nfl advice nba mlb nhl soccer college football betting rocket college basketball dfs wedge live chat classic live sia nejad early edge

Triple Threat Podcast Dynasty Fantasy Football 2025 Mock Draft With 2023-2025 Classes Combined Which WR Gets Taken First Brian Thomas Jr, Puka Nacua, Or Malik Nabers + Can JJ Mccarthy and Bo Nix Have Similar Ceilings Episode 19

Tour Junkies: PGA Tour & Fantasy Golf

Play Episode Listen Later Jun 25, 2025 89:14

Send us a textWELCOME TO THE NEWEST EPISODE OF THE TRIPLE THREAT PODCAST ON THE DYNASTY DNA PODCASTING NETWORK!! In this show the Host of The Dynasty DNA Podcasting Network TJ Blake, Dynasty DNA Team Member and Co Host Nicholas Holt (Dynastywizz) and Dynasty DNA Team Member, Co Host, and The Host of The Dynasty Dogs Podcast Michael Anthony do a mock draft of only the 2023 to 2025 classes combined to see how high and low we are on young dynasty assets ahead of the 2025 NFL season! Which WR gets taken first Brian Thomas Jr, Puka Nacua, or Malik Nabers? We also debate on can JJ Mccarthy and Bo Nix end up having similar ceilings? Lastly, do we trust the ceiling of Marvin Harrison or the floor of JSN more long term? It's a great episode so tune in with us, have a few laughs, and let's get you on your way to dynasty championship in 2025 it all begins this offseason!Join The DNA Strand Crew on Discord Free to Join Just Click This Link!!https://discord.gg/rFAyWzn8Join the DNA Strand Crew on Twitterhttps://mobile.twitter.com/DynastyDNA_Subscribe to The Dynasty DNA YouTube Channel(9) Dynasty DNA Fantasy Football Podcast - YouTubeFollow The DNA Guys On TwitterTJ Blake https://twitter.com/TJBlakeDNAMichael Anthony Michael Anthony (@dynastydogmike) / XNicholas Holt (Dynasty Wizz) Wizz (@DynastyWizzFF) / X

The 2025 Rocket Classic

Play Episode Listen Later Jun 24, 2025 45:00

DB is on vacation (riding horses and sipping mai tai's) so this week Pat and Matt are breaking down everything you need to know about the Rocket Classic! The guys hit on Tommy lad Fleetwood coming up short again on the PGA TOUR, Keegan Bradley as a playing captain for the Ryder Cup and an update on the SZN Long Bet as Matt Every is catching up! The boys dive into the board for the Rocket Classic, who they like at the top, mid-tier plays + top 20 locks and bombs for the field in Detroit. 00:00 Introduction 02:51 Tommy Lad Comes Up Short Again 11:17 Keegan Bradley, Ryder Cup Playing Captain? 16:09 Rocket Classic Preview 22:03 SZN Long Bet Update 25:11 Rocket Classic Odds, Bets & Plays *TJ Ryder Cup 2025 Experience (CONTEST

spotify apple detroit discord contest betting rocket bets linktree pga tour db ryder cup dfs fleetwood keegan bradley matt every tour junkies

Fantasy NBA Today: Celtics & Cavaliers: 2024-25 Fantasy Review & 2025 Offseason Strategy

spotify apple strategy discord offseason google play boston celtics app store cleveland cavaliers eastern conference cavaliers dfs nba today fantasy nba

Play Episode Listen Later Jun 24, 2025 52:30

Join Rick Kamla and Dr. A on Fantasy NBA Today for a deep dive into the Boston Celtics' and Cleveland Cavaliers' 2024-25 seasons and what their crucial 2025 offseasons mean for your fantasy basketball plans. We'll start by deconstructing the Celtics' 2024-25 campaign. What key fantasy insights can we glean from their performance, and how will their roster dynamics be impacted as they look to build on their season? We'll assess the fantasy landscape for each of their core players. Then, we shift our focus to the Cleveland Cavaliers. We'll break down their 2024-25 fantasy performances, identifying who truly delivered and who left us wanting more. More importantly, we'll analyze their impending 2025 offseason: What strategic moves are the Cavaliers likely to make to build on their foundation and push deeper into the playoffs? How will potential trades, or free agency signings impact the fantasy values of their key players? This episode provides essential, timely insights for understanding the fantasy implications of these two Eastern Conference contenders as they head into a pivotal offseason. Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS—perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips!

Golf DFS Preview - 2025 Rocket Classic Picks, Strategy | The Early Wedge

Play Episode Listen Later Jun 24, 2025 52:54

Sia Nejad and Mike McClure preview the 2025 Rocket Classic from a DFS perspective with picks, strategy and more for Detroit Golf Club. (0:00) Intro + a full field, no cut event to tackle this week (2:30) Course Breakdown: Detroit Golf Club (5:45) 10k+ | “I don't want to play any of these guys” (11:08) 9k | There are three main guys in this range (18:20) 8k | Past champions and close calls all over the place…but we aren't playing them (25:00) 7k | Is the lower 7k the place to be? Sia and Mike think yes (36:40) 6k | Are we getting to this range this week? #SportsBetting #Gambling #Betting #DraftKings #FantasySports #FantasyGolf #PGATour #PGADFS #RocketClassic #RocketMortgageClassic #EarlyWedge #EarlyWedge #golf

tv spotify tiktok head apple strategy nfl nba mlb nhl golf soccer college football rocket college basketball sia dfs wedge detroit golf club mike mcclure sia nejad early edge

Rocket Classic Podcast Preview

Fantasy Golf Insider

Play Episode Listen Later Jun 24, 2025 57:32

Fantasy Golf Insider's Jeff Bergerson and Zachary Turcotte preview the 2025 Rocket Classic. Premium content, tools, strategy, and analysis for FGI members: http://www.fantasygolfinsider.com Football Insider Edge: https://www.footballinsideredge.com/ FGI Podcast on iTunes: https://itunes.apple.com/us/podcast/fantasy-golf-insider/id1055153112?mt=2 FGI Podcast on Stitcher: http://www.stitcher.com/podcast/fantasy-golf-insider

club masters tour open fantasy champions championship golf stitcher tournament classic rocket pga draftkings dfs golfing 2025 fgi fantasyaces jeff bergerson

GI Cancer Research at ASCO25: Plenary Highlights and More

ASCO Daily News

Play Episode Listen Later Jun 24, 2025 20:47

Dr. Shaalan Beg and Dr. Kristen Ciombor discuss practice-changing studies in GI cancers and other novel treatment approaches that were presented at the 2025 ASCO Annual Meeting. Transcript Dr. Shaalan Beg: Hello, I'm Dr. Shaalan Beg, welcoming you to the ASCO Daily News Podcast. I'm a medical oncologist and an adjunct associate professor at UT Southwestern Medical Center in Dallas, Texas. There were some remarkable advances in gastrointestinal cancers that were presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Kristen Ciombor to discuss some exciting GI data. Dr. Ciombor is the Ingram Associate Professor of Cancer Research and a co-leader of Translational Research and the Interventional Oncology Research Program at the Vanderbilt Ingram Cancer Center. Our full disclosures are available in the transcript of this episode. Dr. Ciombor, it's great to have you on the podcast today. Dr. Kristen Ciombor: Thanks, Dr Beg. It's great to be here. Dr. Shaalan Beg: Alright, let's kick it off. Big year for GI cancers. We'll start off with LBA1. This was the ATOMIC study sponsored by NCI and the National Clinical Trials Network (NCTN) and the Alliance group. This is a randomized study of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for stage III mismatch repair deficient colorectal cancer. Dr. Kristen Ciombor: I think this study was really definitely practice-changing, as you can tell because it was a Plenary. But I do have some concerns in terms of how we're actually going to implement this and whether this is the final answer in this disease subtype. So, as you said, the patients were enrolled with stage III resected mismatch repair deficient colon cancer, and then they were randomized to either modified FOLFOX6 with or without atezolizumab. And that's where it starts to become interesting because not many of us give FOLFOX for 6 months like was done in this study. Obviously, the study was done over many years, so that was part of that answer, but also the patients received atezolizumab for a total of 12 months. So the question, I think, that comes from this abstract is, is this practical and is this the final answer? I do think that this is practice-changing, and I will be talking to my patients with resected mismatch repair deficient colon cancer about FOLFOX plus atezolizumab. I think the big question is, do these patients need chemotherapy? And can we do a neoadjuvant approach instead? And that's where we don't have all the answers yet. Dr. Shaalan Beg: Yeah, but it has been great to see immunotherapy make its way into the adjuvant space after having made such a big impact in the metastatic space, but still some unanswered questions in terms of the need for chemotherapy and then the duration of therapy, which I guess we'll have to stay tuned in for the next couple of years to to get a lot of those questions answered. Dr. Kristen Ciombor: Yeah, but a big congratulations to the study team, to the NCTN, the NCI. I mean, this is really a great example of federally funded research that needs to continue. So, great job by the study team. The DFS 10% difference is really very large and certainly a practice-changing study. Dr. Shaalan Beg: Yeah, and and sticking with colon cancer, and and this another federally funded study, but this time funded by a Canadian cancer clinical trials group was LBA3510. This is the CHALLENGE study. It's a randomized phase 3 trial of the impact of a structured exercise program on disease-free survival for stage III or high-risk stage II colon cancer. This study got a lot of buzz, a lot of mainstream press coverage, and a lot of discussions on what that means for us for the patients who we're going to be seeing next week in our clinic. What was your takeaway? Dr. Kristen Ciombor: Yeah, this is a really interesting study, and I was so glad to see it presented because this partially answers one of the questions that patients always have for us in clinic, right? You know, once they've completed their standard chemotherapy and surgery, what else can they do to help prevent recurrence? And so we've always known and sort of extrapolated that healthy lifestyle habits are good, but now we have data, particularly in these patients. Most of them were stage III colon cancer patients, those had high-risk stage II cancer. And basically, the goal was to increase their physical activity by at least 10 MET hours per week. So, my big question, of course, as I came into this presentation was, “Okay, what does that mean exactly? How does that translate to real life?” And really what the author presented and explained was that basically most patients could hit their target by adding a 45- to 60-minute brisk walk 3 to 4 times a week. So I think this is very approachable. Now, in the confines of the study, this was a structured exercise program, so it wasn't just patients doing this on their own. But I do think kind of extrapolating from that, that this is very achievable for most patients. And not only did this prevent recurrence of their prior cancer, but actually the rate of new primary cancer diagnoses, was less, which is really interesting, especially in the breast and prostate cancer. So this was a really interesting, and I think practice-changing study as well, especially given that this is something that most patients can do. Dr. Shaalan Beg: Yeah, and there was a lot of discussion in the hallways after the presentation in terms of how this really changes our existing practice because most folks already recommend exercise as a way for improving outcomes in cancer patients. So we've already been doing that. Now we have some data on how much it can impact the benefit. But there was some discussion about what the actual degree of impact was. There was a drop-off rate in terms of how long folks were able to stick with this exercise regimen. But you've seen this in clinic when someone have their surgery, they have their chemotherapy, they've been so intimately involved with the oncology world, with the oncology practice, and they somehow feel that they're being let loose into this mean, angry world without any guidance and they're looking for something to do. “What more can I do in terms of my lifestyle?” And then here we have very solid data, as solid as can be for an intervention like exercise, showing that there is an impact and you can give a prescription for exercise when someone wraps up their chemotherapy for colon cancer, thanks to the study. Dr. Kristen Ciombor: Yeah. It was a great study. Dr. Shaalan Beg: Moving to gastroesophageal cancer, another late-breaking abstract. This is LBA5. The MATTERHORN trial was a phase 3 trial of durvalumab plus FLOT for resectable GE junction and gastric cancer. And again, another area where immunotherapy has made an impact, and here we're seeing it move closer for earlier-stage disease. What was your take-home for the MATTERHORN trial? Dr. Kristen Ciombor: Yeah, so this study looked at neoadjuvant perioperative durvalumab plus our current standard chemotherapy of FLOT versus placebo plus FLOT. And this was a large study, almost 1,000 patients were randomized. And the primary endpoint was event-free survival, and it was definitely met in favor of the D + FLOT arm, as Dr. Klempner discussed after Dr Janjigian's presentation. I do think there are still some unanswered questions here. Overall survival is not yet mature, so we do have to wait and see how that shakes out. But it's very interesting and kind of is reflective of what, as you said, we're looking at earlier and earlier lines of therapy, particularly with immunotherapy, in these GI cancer spaces. So it makes a lot of sense to test this and and to look at this. So the toxicity was pretty similar to what we would expect. Primary endpoint was met, but again, we'll have to wait and see what the survival data looks like. Dr. Shaalan Beg: Yeah, and in oncology, we know, especially for treatment that does add additional cost, it does add additional potential toxicity that we want to see that overall survival nudged. I did see some polls on social media asking folks whether their practices changed from this, and I think the results were favoring adding durvalumab for this group of patients but understanding that there are caveats to the addition of treatments and the eventual FDA approval in that indication as well. Dr. Kristen Ciombor: Exactly. I completely agree with that. Dr. Shaalan Beg: All right. How about we stick with gastroesophageal cancer? LBA4002 was trastuzumab deruxtecan versus ramucirumab plus paclitaxel for second-line treatment in HER2-positive unresectable or metastatic gastric cancer or GE junction cancer. This was the DESTINY-Gastric04 study. And again, antibody-drug conjugates making a big impact across different diseases. And here we have more data in the HER2-positive gastric cancer space. Your thoughts on this study? Dr. Kristen Ciombor: Yeah, so this is a really important space in gastroesophageal cancer because the HER2 positivity rate is fairly high as compared to some of our other tumor types. So, I do think one of the important things was that patients did have biopsy confirmation of HER2 status, which was very important, and then they were randomized to either T-DXd versus the kind of second-line standard of ramucirumab-paclitaxel. So this was a great practical study and really answers a question that we had for a while in terms of does anti-HER2 therapy in the second-line really impact and improve survival. So we did see a statistically significant improvement favoring T-DXd. I do think it's always important to look at toxicity, though, too. And there was about almost 14% rate of interstitial lung disease, which of course is the most feared toxicity from some of these antibody-drug conjugates, especially T-DXd. So I do think it's important to keep that in mind, but this is definitely a great addition to the armamentarium for these HER2-positive patients. Dr. Shaalan Beg: And pancreas cancer was on the stage after a very long time with a positive clinical trial. This is Abstract 4006. These were preliminary results from a phase 2 study of elraglusib in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel alone for previously untreated metastatic pancreas cancer. This is a frontline clinical trial of gemcitabine/nab-paclitaxel plus/minus the study drug. There were other cohorts in this study as well, but they reported the results of their part 3B arm. And great to see some activity in the pancreas space. And your thoughts? Dr. Kristen Ciombor: Yeah, we definitely need better treatments in pancreas cancer. This was a very welcome presentation to see. The elraglusib is an inhibitor of GSK-3beta, and it's thought that that mediates drug resistance and EMT. And so this is, I think, a perfect setting to test this drug. So patients basically were randomized. Patients with metastatic pancreas cancer were randomized 2: 1 to gemcitabine/nab-paclitaxel plus or minus this elraglusib. So, what we saw was that overall survival was better with the addition of this new drug. And overall, not only the 1-year overall survival, but also median overall survival. The thing that was interesting, though, was that we saw that the overall survival rates were 9.3 months with the combination versus 7.2 months with just gemcitabine/nab-paclitaxel. And that's a little bit lower than we've seen in other studies. So, not sure what was going on there. Was it the patients that were a bit sicker? Was it a patient selection, you know, thing? I'm not really sure how to explain that so much. Also, the toxicity profile was much higher in terms of visual impairment, with over 60% of patients being treated with the combination versus 9% with gemcitabine/nab-paclitaxel. So these were mild, grade 1 and 2, but still something to be cautious about. Dr. Shaalan Beg: And especially with this being a phase 2 trial, making sure that in a larger study we're able to better evaluate the toxicity and see if the control arm in the larger confirmatory study performs differently will be really important before this compound makes it to the clinic in our space. But very exciting to see these kinds of results for pancreas adenocarcinoma. Dr. Kristen Ciombor: Yeah. Dr. Shaalan Beg: We've talked, it seems, a couple of times on this podcast about the BREAKWATER clinical trial. We did hear PFS and updated OS data, updated overall survival data on first-line encorafenib plus cetuximab plus modified FOLFOX6 for BRAF-mutated colorectal cancer. This was LBA3500. And eagerly anticipated results – we have all previously heard the progression-free survival results – but here we heard updated overall survival results, and very well-received study it seemed from the audience that time. So what are your takeaways on the updated results for BREAKWATER? Dr. Kristen Ciombor: In my opinion, this was one of the most practice-confirming studies. As you mentioned, we've already seen some of the preliminary data of BREAKWATER at prior meetings. But really what was particularly impactful for me was the median overall survival with the BREAKWATER regimen. So, again, patients received FOLFOX, encorafenib cetuximab in the first line if they had BRAF-mutated V600E-mutated colorectal cancer. And the median PFS was 12.8 months, which was actually really remarkable in this traditionally very aggressive, poor prognosis subtype of tumors. So, by seeing a median overall survival of 30.3 months was just incredible, in my opinion. Just a few years ago, that was considered the median overall survival for all comers for metastatic colorectal cancer. And we know the median overall survival was more in the less than 12 months range for BRAF. So this was incredibly impactful, and I think should be absolutely practice-changing for anyone who is eligible for this regimen. I think again, where the practice meets the study is what's kind of important to think about too, how long did patients get FOLFOX, and certainly it adds toxicity to add a BRAF-targeted regimen on top of FOLFOX already. So, one of the other interesting things about the study, though, was that even though it didn't complete treatment, they actually did look at encorafenib/cetuximab alone and in the first line without chemotherapy. And those preliminary results actually looked okay, especially for patients who might not be able to tolerate chemotherapy, which we certainly see in practice. So, overall, definitely more data. And I agree that it's certainly practice-changing. Dr. Shaalan Beg: And it completely, as you mentioned, changes the outlook for a person who's diagnosed with BRAF-mutated metastatic colon cancer today versus even 7 or 8 years ago. Dr. Kristen Ciombor: And we're seeing this over and over in other subtypes too, but how you choose to treat the patient up front really matters. So really giving the right regimen up front is the key here. Dr. Shaalan Beg: And along the same lines, Abstract 3501 wanted to answer the question on whether people with MSI-high metastatic colorectal cancer need double checkpoint inhibitor therapy or is single therapy enough. So this [CheckMate-8HW] study compared nivo plus ipi with nivo alone, nivo monotherapy for MSI-high metastatic colorectal cancer. And we've known that both of these are fairly active regimens, but we also know the chance of immune-related adverse events is significantly higher with combination therapy. So this was a much-needed study for this group of patients. And what were your takeaways here? Dr. Kristen Ciombor: This, of course, has been really nivo-ipi in the first-line MSI-high metastatic colorectal cancer is now a standard of care. And not everybody is eligible for it, and there could be reasons, toxicity reasons, and other things too. But as we've been seeing for the last couple of years, immunotherapy clearly beats chemo in this space. And now looking at doublet versus single immunotherapy treatment in the first line, I think really nivo-ipi does beat out monotherapy. I will say, however, there is a caveat in that we still haven't seen the nivo-ipi versus nivo in the first line. So what has been presented thus far has been across all lines of therapy, and that does muddy the waters a little bit. So definitely looking forward and and we've asked this many times and based on the statistical plan and and what not, you know, we just haven't seen that data yet. But I do think it's becoming increasingly important to consider doublet immunotherapy for these patients as long as there are no contraindications. With the again, with the caveat that we have to have these toxicity discussions in the clinic with patients because many patients can tolerate it, you know, this regimen fairly well, but there can be very severe toxicities. So, I think an informed discussion should really be had with each patient before moving forward. Dr. Shaalan Beg: Yeah, informed decision, making them aware of the potential of real significant toxicities, immune-related toxicities with double therapy. But I am curious in your practice, how often do you see people choosing doublet therapy as frontline? Dr. Kristen Ciombor: So patients are really savvy, and a lot of times they've heard this data before or have come across it in patient advocacy groups and other things, and it's really nice to be able to have that conversation of the risk versus benefit. So I will say not all of my patients choose doublet, and many of them are still cured with immunotherapy monotherapy. So the big question there is, will we ever understand who actually needs the doublet versus who can still be cured or have very good long-term outcomes with just the single agent? And that has not been answered yet. Dr. Shaalan Beg: What a great point. So the last abstract I was hoping we could talk about is POD1UM-303 or the INTERAACT2 subgroup analysis and impact of delayed retifanlimab treatment for patients with squamous cell carcinoma of the anal canal. What were your thoughts here? Dr. Kristen Ciombor: This was a study, actually we saw at ESMO, we saw the primary data at ESMO last year, and this was an update with some exploratory analyses. But this was really an important study because once again, we're looking at immunotherapy in later lines of therapy. That's how we started looking at and investigating immunotherapy, and now we're moving it up and up in the treatment course. So this was a study of carboplatin/paclitaxel plus or minus retifanlimab. Actually it was retifanlimab versus placebo. And it was a positive study, as we heard last year. This actually led to FDA approval of this regimen last month, just before ASCO, and it has now been incorporated in the NCCN guidelines as the preferred first-line option. So what I thought was important from the additional data presented at ASCO was looking at the different subgroups, it did not appear that patients with liver mets or not had different outcomes. So that was really good to see because sometimes in colon cancer we see that immunotherapy doesn't work as well when patients have liver mets. And interestingly, because we use immunotherapy in anal cancer without any biomarkers, unlike with colon cancer or some of the other tumor types, also the authors looked at PD-L1 status, and it did look like maybe patients did a little bit better if they had higher PD-L1 expression, but patients still could benefit even if they were PD-L1 negative. So that was important, I think, and we will continue to see further data come out from this study. I want to mention also that EA2176 just completed accrual, so that was carbo-taxol plus or minus nivolumab. And so we should be seeing that data sometime soon, which will hopefully also confirm the ongoing role for immunotherapy in the first-line setting for anal cancer. Dr. Shaalan Beg: That was a fantastic review. Thank you, Dr Ciombor. Thanks for sharing your valuable insights with us today on the ASCO Daily News Podcast. Dr. Kristen Ciombor: Thanks for having me here. Dr. Shaalan Beg: And thank you to our listeners for your time today. You will find links to the abstracts discussed today in the transcript of this episode. And if you value the insights that you hear on the podcast, please take a moment to rate, review, and subscribe, wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:  Dr. Shaalan Beg @ShaalanBeg  Dr. Kristen Ciombor @KristenCiombor Follow ASCO on social media:   @ASCO on Twitter  @ASCO on BlueSky ASCO on Facebook   ASCO on LinkedIn   Disclosures:  Dr. Shaalan Beg:  Consulting or Advisory Role: Ipsen, Cancer Commons, Foundation Medicine, Science37, Nant Health, Lindus Health Speakers' Bureau: Sirtex Research Funding (Inst.): Delfi Diagnostics, Universal Diagnostics, Freenome Dr. Kristen Ciombor: Consulting or Advisory Role: Pfizer, Incyte, Exelixis, Bayer, ALX Oncology, Tempus, Agenus, Taiho Oncology, Merck, BeiGene Research Funding (Inst.): Pfizer, Boston Biomedical, MedImmune, Onyx, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Novartis, Incyte, Amgen, Sanofi, Bristol-Myers Squibb, Array BioPharma, Incyte, Daiichi Sankyo, Nucana, Abbvie, Merck, Pfizer/Calthera, Genentech, Seagen, Syndax Travel, Accommodations, Expenses: Incyte, Tempus

Market Monday: How To Adjust Strategy As ADPs Change (Episode 874 with Adam Levitan)

Play Episode Listen Later Jun 23, 2025 12:32

Adam Levitan looks at the most interesting risers & fallers in average draft position from the last seven days. Is he buying or selling these players at their new prices?Show NotesIn this episode, we discuss:Emeka EgbukaLast-round WRsJaylin Noel Terry McLaurinTons moreWant ETR on your team this season? Our 2025 NFL Best Ball Product has you covered with:Real-Time RankingsResearch & Analysis ArticlesDraft Strategy ContentDraft LivestreamsDiscord CommunityQ&As with ETR TeamSubscribe now at https://subscribe.establishtherun.com/nflbestball/Download the DraftKings Daily Fantasy app now to draft your $20 Best Ball lineup toplay for a share of $15 million—and get a second ticket to play FREE for a share of $15million. That's two chances to win big without ever setting your lineup again. Draft One,Get One—only on DraftKings. The Crown Is Yours.https://dkng.co/BestBallETRGambling Problem? Call 1-800-GAMBLER or 877-8-HOPENY/text HOPENY (467369) (NY). Help is available for problem gambling. Call (888) 789-7777 or visit ccpg.org (CT).18+ in most eligible states, but age varies by jurisdiction. Eligibility restrictions apply. Void where prohibited. 1 per customer. Must enter a lineup into the NFL Best Ball $15M Headliner Contest by 9/4/25. $20 entry fee. Bonus issued as 1 ticket to NFL Best Ball $15M Headliner Contest. Ticket reward is site credit valid for use only on NFL Best Ball $15M Headliner Contest. Ticket reward is single-use and expires on the sooner of 30 days (720 hours) or contest lock. See terms at https://www.draftkings.com/nfl-best-ball. Ends 9/4/25 at 6:20 PM ET. Sponsored by DK.DFS OPTIMIZER: Sign up for THE SOLVER for access to the software we think fantasy players need to win: https://thesolver.com/?ref=etrWE CAN HELP: Tired of attention-seeking hot takes? Get the highest-quality fantasy football analysis in your inbox, FREE: https://bit.ly/establishtherunSPORTSBOOK OFFERS: We've partnered with several major sportsbook outlets to help supply you with the best offers in the industry and ensure you're maximizing your bankroll from the start: https://establishtherun.com/offers/FOLLOW US: Check out our social media channels for FREE fantasy football & DFS videos, analysis, and more: https://linktr.ee/establishtherun

strategy ny ends ticket void draftkings gambler eligibility dk dfs get one hopeny best ball solver adam levitan market monday crown is yours draftkings daily fantasy

Warriors & Nuggets: Strategic Moves & Fantasy Implications

spotify apple fantasy discord warriors strategic google play denver nuggets implications app store golden state warriors dfs

Play Episode Listen Later Jun 23, 2025 66:57

Join Rick Kamla and Dr. A on Fantasy NBA Today for a comprehensive review of the Golden State Warriors and Denver Nuggets' 2024-25 seasons, entirely through a fantasy lens. We're uncovering the key fantasy takeaways from their performance and peering into what the 2025 offseason holds. This episode will provide an honest assessment of players who surprised us with their fantasy impact and those who disappointed. More importantly, we'll analyze the critical offseason period for both franchises: What strategic moves are the Warriors likely to make to extend their competitive window? How will the Nuggets adjust their championship-contending roster? Which free agency decisions or draft picks could reshape the fantasy landscape for both teams? Get ready for an episode packed with actionable fantasy insights, detailed player breakdowns, and the foresight you need to dominate your drafts. Don't miss this essential guide to the Warriors and Nuggets offseason! Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS—perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips!

The Heat-tastic Review | UFC Fight Night Baku: Hill vs. Roundtree Jr.

Dr Roto Media Network

Play Episode Listen Later Jun 23, 2025 27:31

In this episode of Bring the Pain, I reviewed yesterday's UFC Fight Night in Baku, which featured Jamahal Hill vs. Khalil Roundtree Jr. I break everything down fast since we have 12 fights to cover, with one almost giving us another zany finish like last week. After that, I talked about drafting live for my SFB 15 team and talking about all of the great fantasy football content we have at Dr. Roto. Have a great day, everyone, and may the fights be with you.

sports pain fantasy heat baku dfs ufc fight night roto jamahal hill sfb roundtree

Best Ball Live Draft + Sniping Stacks - Fantasy Football DFS & Betting

Fantasy Footballers DFS - Fantasy Football Podcast

Play Episode Listen Later Jun 20, 2025 57:44

Live Best Ball Draft on today's Fantasy Footballers DFS & Betting podcast! Borg & Betz participate in a live best ball draft on Underdog with the FootClan! Get insights on best ball strategy, stacking, and optimal roster construction. Welcome to “DFS and Sports Betting For The Rest of Us.” Take your DFS and Betting Fantasy Football game to the next level on DraftKings, FanDuel, and Underdog Fantasy. -- Fantasy Football Podcast for June 20th, 2025.Best Ball Rankings available in the 2025 UDK+ at UltimateDraftKit.comConnect with The Fantasy Footballers:Visit us on the WebSupport the ShowFollow on XFollow on InstagramJoin our DiscordLove the show? Leave us a review wherever you listen

fantasy football betting underdogs draftkings stacks fanduel dfs best ball underdog fantasy fantasy football podcasts live draft foot clan sniping udk

Drafting BEAUTIFUL Best Ball Teams For $4.5 MILLION | 2025 Best Ball Draft + Fantasy Football

Splash Play - Fantasy Football Podcast

Play Episode Listen Later Jun 20, 2025 142:18

2025 Best Ball Draft - Chris Spags drafts on the three major best ball sites as he does an Underdog draft, DraftKings draft, and Drafters draft to compete for $4.5 million in first place prizes! What are the current differences between a 2025 best ball draft when you do an Underdog Best Ball Mania draft, DraftKings Millionaire draft, or a Drafters Best Ball Championship draft? What's the training camp buzz that matters most on each site? Let's find out! SUPPORT SPLASH PLAY! 👇 🏈 $100 deposit match on Drafters, code SPLASH https://drafters.com/?ref=splash 📝 Get Spags' updates on NFL news and rumors for best ball https://www.oddsshopper.com/expert-picks/experts/view/chrisspags/subscribe 📈 15% off Stokastic DFS tools and data, code SPLASH https://www.stokastic.com/join?aff=chrisspags 🛍️ 50% off OddsShopper's PortfolioEV betting tools https://www.oddsshopper.com/?via=splash 🎲 20% off Unabated with code SPLASH https://unabated.com/?ref=splash 🔎 Try ETR's The Solver with code SPLASH https://fas.st/t/q3FYdKpj 🤗 Join Splash Play to get a VIP Discord and Spags' rankings https://www.youtube.com/channel/UCtocTNLM4KH8UiEOHjOvt2Q/join 💬 When you join, connect YouTube to your Discord to get the Squirt Squad premium channels https://discord.gg/mPf6hAEYt4 📺 Subscribe for YEAR ROUND fantasy football content: https://www.youtube.com/@splashplaypod?sub_confirmation=1 🎧Podcast version https://podcasts.apple.com/us/podcast/splash-play-fantasy-football-podcast/id1531045853 💦 Keep up with Splash Play: https://twitter.com/splashplaypod 🐦 Follow Chris Spags! https://twitter.com/ChrisSpags 👕 Get Splash Play merch https://overzet.myshopify.com/collections/splash-play Timestamps: 0:00 Intro 0:45 Underdog Best Ball Mania draft (Saquon Bucky Jayden) 3:30 Spags' BBM exposures so far 19:30 Cam Skattebo's Bucky Irving case 27:30 A believable case for Daniel Jones 35:10 Team review 39:20 DraftKings Best Ball Milly Maker draft (Another Saquon Bucky team!) 44:00 Ideal robust RB builds 52:30 Olave vs Addison: Who's better? 1:02:00 Tre Harris's case for and against 1:15:00 Iosivas worth a click? 1:24:28 Team review 1:36:40 Drafters Main Event draft (Bucky Jefferson McBride) 1:39:00 The importance of knowing ADP pockets 1:51:00 Mostert's value behind Jeanty 1:57:00 Drake Maye's overhyping 2:04:30 Deebo and Spags' 2025 Commanders take 2:18:55 Team review 2:20:15 Outro #bestballdraft2025 #2025fantasyfootball #drafters #underdog #draftkings #bestballdraft #bestball2025 ===== 2025 best ball draft, 2025 fantasy football, best ball, best ball fantasy football, drafters draft, 2025 best ball, 2025 underdog draft, 2025 drafters draft, 2025 draftkings best ball draft, 2025 nfl rookies, 2025 nfl rookie rankings, 2025 fantasy football rankings, best ball 2025, best ball draft 2025, underdog draft 2025, draftkings best ball draft 2025, drafters best ball draft 2025

nfl football team fantasy discord ideal fantasy football underdogs rb splash commanders drafting draftkings adp dfs year round deebo chris olave best ball bbm solver spags bucky irving drafters tre harris unabated oddsshopper splash play

The Dynasty DNA Deep Dive Dynasty Fantasy Football 2025 NFC North Breakdown Is Jameson Williams A Buy Or A Sell + Who Will Be The Long Term Better Dynasty Asset In Chicago Colston Loveland Or Luther Burden + Will Jordan Love Have A Bounce Back Episode 8

Play Episode Listen Later Jun 20, 2025 87:04

Send us a textWELCOME TO THE NEWEST EPISODE OF THE DYNASTY DNA DEEP DIVE PODCAST ON THE DYNASTY DNA PODCASTING NETWORK!! This show will be releasing every Friday with the Host of The Dynasty DNA Podcast TJ Blake, Dynasty DNA Team Member Bob Helfert (AKA Big Bob) and Dynasty DNA team member Noah Hutchinson (AKA SLIM)! In this episode we breakdown the NFC as a Division ahead of the 2025 season! We talk things such as what's our thoughts on Jameson Williams is he more of a buy or a sell for us this offseason! We also discuss who will be the better long term dynasty asset for the Chicago Bears Colston Loveland or Luther Burden! Lastly, will Jordan Love have a bounce back for the Packers this season? It's a great episode so tune in with us, have a few laughs, and let's get you on your way to dynasty championship in 2025 it all begins this offseason!Join The DNA Strand Crew on Discord Free to Join Just Click This Link!!https://discord.gg/rFAyWzn8Join the DNA Strand Crew on Twitterhttps://mobile.twitter.com/DynastyDNA_Subscribe to The Dynasty DNA YouTube Channel(9) Dynasty DNA Fantasy Football Podcast - YouTubeFollow The DNA Guys On TwitterTJ Blake https://twitter.com/TJBlakeDNABob Helfert Bob Helfert (@BigefatBob) / XNoah Hutchinson Noah Hutchinson (@12thmanfantasy1) / X

Timberwolves, Knicks & NBA Finals: Season Review & Game 6 Betting Angles

spotify game apple nba discord nba finals google play finals new york knicks betting app store timberwolves angles minnesota timberwolves game 6 dfs

Play Episode Listen Later Jun 19, 2025 59:53

Join Rick Kamla and Dr. A on Fantasy NBA Today for a comprehensive episode breaking down two dynamic NBA franchises and, in the spirit of the ongoing excitement, our expert betting angles for a potential NBA Finals Game 6! We're starting with an in-depth look at the Minnesota Timberwolves and New York Knicks 2024-25 seasons. We'll identify their fantasy success stories and disappointments, providing clear insights into their overall team performance and what it means for individual player values. What strategic offseason moves might each team make, and how will those impact your fantasy draft plans? Following our team deep dives, we'll shift our focus to the NBA Finals. If the series were to reach a critical Game 6, we'd be offering our best bets and sharp analysis, discussing key matchups, player props, and betting trends to guide your decisions. This episode is a must-listen for fantasy managers and basketball enthusiasts eager for insightful analysis and, hypothetically, a betting edge on the Finals! Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS—perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips!

CFL Week 3 Preview, Picks & DFS | The CFL Gambling Podcast (EP. 91)

Play Episode Listen Later Jun 19, 2025 59:25

In this episode of the CFL Gambling Podcast, hosts Colby Dant and Justin Mark discuss their picks, previews, and DFS (Daily Fantasy Sports) strategies for week three of the CFL season. They cover news updates, key injuries, and player performances.Colby and Justin analyze each matchup, providing insights and betting tips for each game. They highlight players to watch in DFS lineups and share their favorite props and anytime touchdown bets. The hosts also unveil their signature 'Huge Tits Parlay', an exciting multi-game parlay that promises big returns.Don't miss this deep dive into CFL action, including special segments on team dynamics and underdog picks. Join in on YouTube and Twitter for live discussions and gambling advice.00:00 Intro04:05 Injury Updates and Player News10:13 CFL Week 3 Picks20:29 Betting Tips and Final Thoughts30:49 Analyzing Week Two Player Props31:22 Ottawa vs Calgary: Game Script Concerns32:53 First Touchdown Bets and Player Props33:18 Thursday and Friday Night Plays36:21 DFS Picks and Strategies39:39 Huge Tits Parlay and Final Thoughts Exclusive SGPN Bonuses And Linkshttp://linktr.ee/sportsgamblingpodcastFollow The Sports Gambling Podcast X/Twitter - https://x.com/GamblingPodcastInstagram - https://www.instagram.com/sportsgamblingpodcastTikTok - https://www.tiktok.com/@gamblingpodcastFacebook - http://www.facebook.com/sportsgamblingpodcastFollow The Sports Gambling Podcast HostsSean Green - http://www.twitter.com/seantgreenRyan Kramer - http://www.twitter.com/kramercentricGambling problem? Call 1-800-GAMBLER CO, DC, IL, IN, LA, MD, MS, NJ, OH, PA, TN, VA, WV, WY Call 877-8-HOPENY or text HOPENY (467369) (NY) Call 1-800-327-5050 (MA)21+ to wager. Please Gamble Responsibly. Call 1-800-NEXT-STEP (AZ), 1-800-522-4700 (KS, NV), 1-800 BETS-OFF (IA), 1-800-270-7117 for confidential help (MI)

ms dc md va tn ottawa ks nv cfl wv dfs hopeny bets off ia next step az betting tips gambling podcast ny call cfl week gambler co

CFL Week 3 Preview, Picks & DFS | The CFL Gambling Podcast (EP. 91)

NFL Gambling Podcast

Play Episode Listen Later Jun 19, 2025 59:25

In this episode of the CFL Gambling Podcast, hosts Colby Dant and Justin Mark discuss their picks, previews, and DFS (Daily Fantasy Sports) strategies for week three of the CFL season. They cover news updates, key injuries, and player performances.Colby and Justin analyze each matchup, providing insights and betting tips for each game. They highlight players to watch in DFS lineups and share their favorite props and anytime touchdown bets. The hosts also unveil their signature 'Huge Tits Parlay', an exciting multi-game parlay that promises big returns.Don't miss this deep dive into CFL action, including special segments on team dynamics and underdog picks. Join in on YouTube and Twitter for live discussions and gambling advice.00:00 Intro04:05 Injury Updates and Player News10:13 CFL Week 3 Picks20:29 Betting Tips and Final Thoughts30:49 Analyzing Week Two Player Props31:22 Ottawa vs Calgary: Game Script Concerns32:53 First Touchdown Bets and Player Props33:18 Thursday and Friday Night Plays36:21 DFS Picks and Strategies39:39 Huge Tits Parlay and Final Thoughts Exclusive SGPN Bonuses And Linkshttp://linktr.ee/sportsgamblingpodcastFollow The Sports Gambling Podcast X/Twitter - https://x.com/GamblingPodcastInstagram - https://www.instagram.com/sportsgamblingpodcastTikTok - https://www.tiktok.com/@gamblingpodcastFacebook - http://www.facebook.com/sportsgamblingpodcast Gambling problem? Call 1-800-GAMBLER CO, DC, IL, IN, LA, MD, MS, NJ, OH, PA, TN, VA, WV, WY Call 877-8-HOPENY or text HOPENY (467369) (NY) Call 1-800-327-5050 (MA)21+ to wager. Please Gamble Responsibly. Call 1-800-NEXT-STEP (AZ), 1-800-522-4700 (KS, NV), 1-800 BETS-OFF (IA), 1-800-270-7117 for confidential help (MI)

ms dc md va tn gambling ottawa ks nv cfl wv dfs hopeny bets off ia next step az betting tips gambling podcast ny call cfl week gambler co

Travelers Championship 2025 DraftKings Picks & Lineups | Final Bets, Weather, One & Done Picks

Pat Mayo Experience

Play Episode Listen Later Jun 18, 2025 85:06

Pat Mayo and Tyler Tamboline discuss their favorite 2025 Travelers Championship Bets, DFS picks, debate the best roster construction for the week and project ownership for DFS guaranteed prize pools (GPPs). Plus, they review the DFS Ownership and pivot plays. Use code “MAYO” at underdog for a deposit match up to $1000:Get 20% off https://www.fantasynational.com/mayo with code “MAYO”Win a golf trip to Cabot Links at Coolbet: https://shorturl.at/4Ckgd. “SPORTS200” to get a bonus $200 too.DEGEN75 GO FUND ME : https://x.com/ToeTagginTambo/status/1927471560866054146 Travelers Championship — For tickets and information visit TravelersChampionship.com. The Travelers Championship, there is only one! June 18th through the 22ndOMAHA STEAKS — Go to https://www.OmahaSteaks.com to get 50% off sitewide during their Fourth of July Sale. And use Promo Code MAYOat checkout for an extra $45 off. Minimum purchase may apply. See site for details. A big thanks to our advertiser, Omaha Steaks!CARGURUS — Buy or sell your next car today with Car Gurus at cargurus.comTOUR STRIKER - Head to tourstriker.com/TSGA and use the code MAYO to get your first month of the Tour Striker Golf Academy Online free, plus instant access to two bonus courses—'The Recipe for Better Golf' and 'Bombs: How to Consistently Smash the Driver,' a $194 value. Subscribe, Rate and ReviewApple: http://bit.ly/PMEiTunesSpotify: https://goo.gl/VboemH FOLLOW MAYO MEDIA NETWORKNewsletter: https://mayomedia.substack.com/Instagram: https://www.instagram.com/mayomedianetwork/TIK TOK: https://www.tiktok.com/discover/mayo-media-networkYOUTUBE: https://bit.ly/YTMMN SHOW INDEX00:00 Intro00:56 US Open DK Recap16:34 Slate Overview21:14 Bets31:09 OAD42:01 Underdog/Weather52:03 DK Lineups1:12:19 Q&A Message and data rates apply. Must be 18+ (21+MA & AZ, 19+ AL, NE) and present in a state where Underdog Fantasy operates. Terms apply. Concerned with your play? Call 1-800-GAMBLER or visit www.ncpgambling.org; AZ: 1-800-NEXT-STEP (1-800-639-8783) or text NEXT-STEP to 53342; NY: Call the 24/7 HOPEline at 1-877-8-HOPENY or Text HOPENY (467369)

The NFL Futures Bets We're Making Right Now (Episode 873 with Evan Silva, Adam Levitan, special guest Tyler Fulghum)

Play Episode Listen Later Jun 18, 2025 41:24

Adam Levitan and Evan Silva take a look at their favorite NFL Futures bets on the market right now alongside ESPN's Tyler Fulghum. In this episode, we discuss:- Which surprise second-year player does Evan believe can lead the league in passing yards?- Why the 49ers could lead the NFL in wins in 2025?- Has the Lions bubble burst already?- Are we all too low on the Dallas Cowboys?- How badly will the vibes in Cincinnati impact the team's on-field performance?Timestamps:0:00 - Intro3:11 - Minnesota Vikings7:40 - Detroit Lions9:59 - Dallas Cowboys15:25 - Carolina Panthers17:29 - New Orleans Saints19:03 - San Francisco 49ers24:51 - Cincinnati Bengals27:52 - New England Patriots32:01 - Tennessee Titans34:12 - Michael Penix37:26 - Week One Opening LinesDownload the DraftKings Daily Fantasy app now to draft your $20 Best Ball lineup to play for a share of $15 million—and get a second ticket to play FREE for a share of $15 million. That's two chances to win big without ever setting your lineup again. Draft One, Get One—only on DraftKings. The Crown Is Yours. https://dkng.co/BestBallETRGambling Problem? Call 1-800-GAMBLER or 877-8-HOPENY/text HOPENY (467369) (NY). Help is available for problem gambling. Call ⁠(888) 789-7777⁠ or visit ⁠ccpg.org⁠ (CT). 18+ in most eligible states, but age varies by jurisdiction. Eligibility restrictions apply. Void where prohibited. One per customer. Enter the Best Ball $15M headliner contest by 9/4/25 to get one bonus entry. $20 entry fee required. Reward expires in thirty days. See terms at draftkings.com/nfl-best-ball. Sponsored by DK.Want ETR on your team this season? Our 2025 NFL Best Ball Product has you covered with:Real-Time RankingsResearch & Analysis ArticlesDraft Strategy ContentDraft LivestreamsDiscord CommunityQ&As with ETR TeamSubscribe now at https://establishtherun.com/subscribe/ DFS OPTIMIZER: Sign up for THE SOLVER for access to the software we think fantasy players need to win: https://thesolver.com/?ref=etrWE CAN HELP: Tired of attention-seeking hot takes? Get the highest-quality fantasy football analysis in your inbox, FREE: https://bit.ly/establishtherunSPORTSBOOK OFFERS: We've partnered with several major sportsbook outlets to help supply you with the best offers in the industry and ensure you're maximizing your bankroll from the start: https://establishtherun.com/offers/FOLLOW US: Check out our social media channels for FREE fantasy football & DFS videos, analysis, and more: https://linktr.ee/establishtherun

nfl san francisco ny espn lions cincinnati reward dallas cowboys void draftkings gambler eligibility dk dfs get one hopeny best ball solver futures bets evan silva adam levitan crown is yours tyler fulghum draftkings daily fantasy

Lakers, Rockets & NBA Finals Reactions

spotify apple discord los angeles lakers reactions nba finals google play finals rockets app store houston rockets dfs crucially lakers rockets

Play Episode Listen Later Jun 18, 2025 58:58

Join Rick Kamla and Dr. A on Fantasy NBA Today for an action-packed episode starting with our immediate thoughts on the NBA Finals Game 5. We'll dissect the final game, discuss the overall series, and reveal what it means for fantasy managers looking at the offseason. Following our Finals commentary, we pivot to a deep dive into two of the league's most talked-about teams: the Los Angeles Lakers and the Houston Rockets. We're providing a thorough recap of their 2024-25 seasons from a fantasy perspective, highlighting unexpected contributors and players who struggled. Crucially, we'll project their 2025 offseason, analyzing: What strategic moves are the Lakers expected to make to retool? How will the Rockets continue to build on their promising trajectory? Which free agency decisions, trades, or draft picks will significantly alter player fantasy values? This episode offers essential fantasy analysis for two teams poised for significant offseason activity, combined with immediate, expert reaction to the conclusion of the NBA Finals. Don't miss these timely insights! Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS—perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips!

Best Of: Travelers Championship Live Chat | Should We Fade U.S. Open Contenders? + Xander vs. JT in OaD, DFS Ownership Projections | The Early Wedge

drive acast us open dfs dough travelers championship kyle murray pga dfs

Play Episode Listen Later Jun 18, 2025 24:32

Let's answer your questions! Sia Nejad and Mike McClure are here for any last minute Travelers Championship betting, DFS or One & Done advice. #SportsBetting #Gambling #Betting #TravelersChampionship #GolfBetting #OneandDone #GolfDFS #FantasySports #sianejad #mikemcclure #PGATour #Golf

PGA Drive For Show, DFS For Dough - Travelers Championship

Print Factory Podcast

Play Episode Listen Later Jun 18, 2025 40:17

Our PGA gurus are here to break down the field for the US Open! Join Justin Van Zuiden (stlcardinals84) & Kyle Murray for Drive for Show, DFS for Dough, your first look at this week's PGA DFS slate. Hosted on Acast. See acast.com/privacy for more information.

NASCAR Pocono Odds: Great American Getaway 400 Betting Preview

Angle of Pursuit

Play Episode Listen Later Jun 18, 2025 48:49

Kyle Robert and Brian Twining get you set for the Great American Getaway 400 as NASCAR takes to the tricky triangle.Kyle and Brian run through the Great American Getaway 400 betting board to see if there is any value prior to practice and qualifying. The guys run through Caesars, Fanduel and BetMGM! They look at outrights, placings and head to head matchups for Pocono. But first they recap the week that was from Mexico. They talk SVG dusting the field. strategy calls and more. Plus they recap the betting card and DraftKings lineups.As a reminder, use code AOP25 for a 100% match deposit up to $100. While you are there make sure you join the COMPLETELY FREE listeners league!https://t.co/EXWgnKQpzsSubscribe to the Green White Checkered our FREE newsletter on Substack for more picks and bets every race day.https://aoppodcast.substack.com/Make sure you tune into The Draft every Wednesday from our friends Win the Race. Make sure to subscribe to their YouTube channel while you are there.https://www.youtube.com/@WINTHERACEP100:00 Intro05:02 Viva Mexico 250 DFS and Betting Recap14:18 Pocono Outright Odds and Targets38:15 Pocono Placings, Head to Heads, and More46:33 Pocono Betting Card Recap

The Travelers Championship☂️2025 Betting Show!

Tour Junkies: PGA Tour & Fantasy Golf

Play Episode Listen Later Jun 17, 2025 55:56

It's a jam packed show as DB and Pat (who opens the show for once and starts off with a must see ad) break down everything TPC River Highlands and the last Signature Event on the PGA TOUR this year. The guys get into JJ Spaun winning the US Open, Oakmont, the weather and some SZN Long picks before jumping into the odds board for the Travelers. *TJ Ryder Cup 2025 Experience (CONTEST

apple discord contest travelers betting us open linktree pga tour db dfs travelers championship oakmont jj spaun tpc river highlands tour junkies

Bucks & Clippers: Uncovering the Fantasy Offseason Secrets

spotify apple secrets fantasy discord offseason google play bucks uncovering los angeles clippers app store milwaukee bucks dfs

Play Episode Listen Later Jun 17, 2025 55:23

Join Rick Kamla and Dr. A on today's Fantasy NBA Today as they go deep on the Milwaukee Bucks and LA Clippers. This isn't your average recap – we're unearthing the hidden truths from their 2024-25 seasons that will directly impact your fantasy league. We'll reveal which players were the ultimate fantasy overachievers and if their success is built to last. Then, brace yourself for the honest breakdown of the biggest fantasy disappointments and our take on their bounce-back potential. But the real gold is in the offseason outlook: What trades are brewing? Which free agency moves will send shockwaves through fantasy drafts? Who are the unsung heroes or forgotten busts we're meticulously watching for the next season? Get ready for an episode packed with actionable fantasy insights, bold predictions, and the kind of in-depth analysis you won't find anywhere else. Don't draft without listening to this! Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS—perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips!

Golf DFS Preview - 2025 Travelers Championship Picks, Strategy | The Early Wedge

Play Episode Listen Later Jun 17, 2025 42:50

Rick Gehman, Sia Nejad and Mike McClure preview the 2025 Travelers Championship from a DFS perspective with picks, strategy and more for TPC River Highlands. (0:00) Intro + Sia's still salty about Sam…and the cutline (or lack thereof) (2:15) Course Breakdown: Travelers Championship and TPC River Highlands (6:53) 10k+ | “Definitely playing Scottie in a no-cut event” (11:59) 9k | Differentiating between the oven and the non-oven of the U.S. Open (18:30) 8k | Some flushers here, which ones do we go for? (23:03) 7k | A lot of names & a lot of interesting ones (29:00) 6k | Finding the value in a no-cut event #SportsBetting #Gambling #Betting #DraftKings #FantasySports #FantasyGolf #PGATour #PGADFS #TravelersChampionship #EarlyWedge #EarlyWedge #golf

Travelers Podcast Preview

Fantasy Golf Insider

Play Episode Listen Later Jun 17, 2025 60:28

Fantasy Golf Insider's Jeff Bergerson and Zachary Turcotte preview the 2025 Travelers Championship. Premium content, tools, strategy, and analysis for FGI members: http://www.fantasygolfinsider.com Football Insider Edge: https://www.footballinsideredge.com/ FGI Podcast on iTunes: https://itunes.apple.com/us/podcast/fantasy-golf-insider/id1055153112?mt=2 FGI Podcast on Stitcher: http://www.stitcher.com/podcast/fantasy-golf-insider

club masters tour open fantasy champions championship golf stitcher tournament classic travelers pga draftkings dfs golfing 2025 travelers championship fgi fantasyaces jeff bergerson

The Heat-tastic Father's Day Review | Usman vs. Buckley

Dr Roto Media Network

Play Episode Listen Later Jun 17, 2025 26:16

In this episode of Bring the Pain, I reviewed last night's UFC Fight Night in Atlanta, which featured Usman vs. Buckley. I talked about how the card started out fast before going flat with decisive the rest of the night. The Five-tastic Picks slayed it once again, going 5-0 this week, raising our total to 60-11. However, this week felt very vanilla on the UFC side of things, so for the second part of this podcast, I went full-on IDP mode. With the recent release of my IDP rankings, I have since released my three defensive tiers articles, only on the Dr. Roto website. So, since that's behind the paywall, I decided to cover one player from each of those articles. That's when I go all-in and show you all why IDP at Dr. Roto isn't just a prescription. It's a way of life for your friendly neighborhood IDP hero. Have a great day, everyone, and may the points be with you.

father sports pain fantasy heat ufc buckley dfs usman ufc fight night roto idp

Fantasy Feud 2025 Dynasty Debates Which WR Has The Longest Most Productive Career JSN, Ladd Mcconkey, Or Garrett Wilson + The Likelihood Of Brock Bowers Finishing TE1 Again In 2025 + How Many Times Can Cam Ward Finish As A QB1 In His Career Episode 87

underdogs bets dfs one and done travelers championship sportsbooks tpc river highlands

Play Episode Listen Later Jun 17, 2025 68:31

Send us a textSign Up and join Underdog Fantasy The greatest Fantasy Football Platform available right now Bestball, Daily Drafts, and Pick Em's use this link to sign up and Underdog Fantasy will match up to $100.00 for your first-time deposit! https://play.underdogfantasy.com/p-dynasty-dnaIn this newest episode of Fantasy Feud this off-season the guys debate many things such as which WR has the longest most productive outlook JSN, Ladd Mcconkey, or Garrett Wilson? We also debate on what's the likelihood of Brock Bowers finishing TE1 again in 2025? Lastly, how many times Cam Ward can finish as a QB1 in his career? It's an awesome episode so, sit back let's have a few laughs, listen to some good debates, and let's talk some dynasty fantasy football! Now it's time we entertain you and possibly help you on your drive to a dynasty championship in 2025!Subscribe to The Dynasty DNA YouTube Channel(9) Dynasty DNA Fantasy Football Podcast - YouTubeJoin the DNA Strand Crew on Twitterhttps://mobile.twitter.com/DynastyDNA_Follow The DNA Guys On TwitterTy Blake https://mobile.twitter.com/DynastyDnaTyRyan Mahle https://mobile.twitter.com/DnyastyDnaMusJimmy Leadbetter Jimmy Leadbetter Jimmy Leadbetter (@ffjleadDNA) / X (twitter.com)Join The DNA Strand Crew On Discord Free To Join Just Click This Link!https://discord.gg/rFAyWzn8

Travelers Championship 2025 Picks and Preview All in One - DFS, Bets, One and Done

Mikeâ€™s Money Picks

Play Episode Listen Later Jun 17, 2025 44:51

On this episode, We go over everything you need to know for the 2025 Travelers Championship. We discuss the host course (TPC River Highlands), we take a look at the relevant data for the week and build a custom model, we take a look at the board and try to identify the best DFS plays and best bets, and then we discuss One and Done Strategy for the week.Link to One and Done spreadsheet (Make a copy for your own): https://docs.google.com/spreadsheets/d/1BuRtLkmOWj08P-KN4VnSd1zApAPHwpy0CNg8nH7hXpY/edit?usp=sharingUse code MCONNOLLY88 on UnderDog to get your first deposit matched! https://t.co/FXNtrz6ZBpLink to Patreon: https://t.co/oKODToDCdOFor all of the best offers and promo codes for DFS sites, Player Props sites, and Sportsbooks, use my site at https://signupexpert.com/mikespicks Link to the Fantasy Corner Discord: https://discord.gg/bUCB6aqQed

Market Monday: Buy Or Sell New Prices On D'Andre Swift, Evan Engram, Rashee Rice, and More (Episode 872 with Adam Levitan)

Play Episode Listen Later Jun 16, 2025 15:43

Adam Levitan identifies players moving in ADP and whether to buy or sell them at their new prices.Show NotesIn this episode, we discuss: • Colts QB situation • Steelers with Aaron Rodgers • Derrick Henry's backups • Broncos WRs • Tons moreDownload the DraftKings Daily Fantasy app now to draft your $20 Best Ball lineup to play for a share of $15 million—and get a second ticket to play FREE for a share of $15 million. That's two chances to win big without ever setting your lineup again. Draft One, Get One—only on DraftKings. The Crown Is Yours.https://dkng.co/BestBallETRGambling Problem? Call 1-800-GAMBLER or 877-8-HOPENY/text HOPENY (467369) (NY). Help is available for problem gambling. Call (888) 789-7777 or visit ccpg.org (CT).18+ in most eligible states, but age varies by jurisdiction. Eligibility restrictions apply. Void where prohibited. 1 per customer. Must enter a lineup into the NFL Best Ball $15M Headliner Contest by 9/4/25. $20 entry fee. Bonus issued as 1 ticket to NFL Best Ball $15M Headliner Contest. Ticket reward is site credit valid for use only on NFL Best Ball $15M Headliner Contest. Ticket reward is single-use and expires on the sooner of 30 days (720 hours) or contest lock. See terms at https://www.draftkings.com/nfl-best-ball. Ends 9/4/25 at 6:20 PM ET. Sponsored by DK.Want ETR on your team this season? Our 2025 NFL Best Ball Product has you covered with: • Real-Time Rankings • Research & Analysis Articles • Draft Strategy Content • Draft Livestreams • Discord Community • Q&As with ETR TeamSubscribe now at https://subscribe.establishtherun.com/nflbestball/DFS OPTIMIZER: Sign up for THE SOLVER for access to the software we think fantasy players need to win: https://thesolver.com/?ref=etrWE CAN HELP: Tired of attention-seeking hot takes? Get the highest-quality fantasy football analysis in your inbox, FREE: https://bit.ly/establishtherunSPORTSBOOK OFFERS: We've partnered with several major sportsbook outlets to help supply you with the best offers in the industry and ensure you're maximizing your bankroll from the start: https://establishtherun.com/offers/FOLLOW US: Check out our social media channels for FREE fantasy football & DFS videos, analysis, and more: https://linktr.ee/establishtherun

ny ends ticket pittsburgh steelers prices swift void draftkings gambler adp eligibility dk dfs buy or sell get one hopeny best ball rashee rice evan engram solver adam levitan market monday crown is yours draftkings daily fantasy

Pistons, Grizzlies & NBA Finals: Reactions & Game 5 Bets

spotify game apple games discord reactions nba finals google play finals app store bets detroit pistons grizzlies memphis grizzlies dfs

Play Episode Listen Later Jun 16, 2025 61:38

Join Rick Kamla and Dr. A on Fantasy NBA Today for a stacked episode diving into fantasy implications for the Pistons and Grizzlies including the Desmond Bane trade, plus a full breakdown of the thrilling NBA Finals! We're starting with a deep dive into the Detroit Pistons and Memphis Grizzlies 2024-25 seasons. We'll assess their fantasy standouts, address player disappointments, and look ahead to their crucial 2025 offseason moves. Which players are primed for a fantasy leap, and who should you approach with caution? Next, we turn our attention to the hottest topic in basketball: the NBA Finals. Get our immediate reactions to Games 3 and 4, discussing the pivotal performances, strategic adjustments, and unexpected turns that are defining this championship series. Finally, for the sharp bettors and fantasy managers, we're laying out our best bets for Game 5! We'll give you the insights and angles you need to make informed decisions. Don't miss this comprehensive episode combining essential fantasy analysis with timely Finals commentary! Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS—perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips!

2025 Travelers Championship DFS Picks | Golf Gambling Podcast (Ep. 514)

newsletter betting us open dfs rory mcilroy bryson dechambeau travelers championship oakmont tpc river highlands scotty scheffler

Play Episode Listen Later Jun 16, 2025 18:33

ms dc md va golf tn ks nv wv dfs hopeny travelers championship bets off ia next step az rbc canadian open gambling podcast ny call gambler co

2025 Travelers Championship DFS Picks | Golf Gambling Podcast (Ep. 514)

Golf Gambling Podcast

Play Episode Listen Later Jun 16, 2025 18:33

In this episode of the Golf Gambling Podcast on the Sports Gambling Podcast Network, Matt Gannon (@Matt_Gannnon_) breaks down the DFS pricing for the 2025 RBC Canadian Open. He gives out all his favorite plays and fades from each price tier in DFS for the 2025 Travelers Championship. JOIN the SGPN community #DegensOnlyExclusive Merch, Contests and Bonus Episodes ONLY on Patreon - https://sg.pn/patreonDiscuss with fellow degens on Discord - https://sg.pn/discordDownload The Free SGPN App - https://sgpn.appCheck out the Sports Gambling Podcast on YouTube - https://sg.pn/YouTubeCheck out our website - http://sportsgamblingpodcast.comSUPPORT us by supporting our partnersUnderdog Fantasy code SGPN - Up to $1000 in BONUS CASH - https://play.underdogfantasy.com/p-sgpnRithmm - Player Props and Picks - Free 7 day trial! http://sportsgamblingpodcast.com/rithmmRebet - Social sportsbook - 100% deposit match promo code SGPN in your app store! ADVERTISE with SGPNInterested in advertising? Contact sales@sgpn.io Follow The Golf Gambling Podcast On Social MediaTwitter - http://www.twitter.com/golfgamblingpodInstagram - http://www.instagram.com/sportsgamblingpodcastTikTok - https://www.tiktok.com/@golfgamblingpodFacebook - http://www.facebook.com/sportsgamblingpodcastFollow The Hosts On Social MediaMatt Gannon - twitter.com/matt_gannonPodcast - twitter.com/golfgamblingpod Gambling problem? Call 1-800-GAMBLER CO, DC, IL, IN, LA, MD, MS, NJ, OH, PA, TN, VA, WV, WY Call 877-8-HOPENY or text HOPENY (467369) (NY) Call 1-800-327-5050 (MA)21+ to wager. Please Gamble Responsibly. Call 1-800-NEXT-STEP (AZ), 1-800-522-4700 (KS, NV), 1-800 BETS-OFF (IA), 1-800-270-7117 for confidential help (MI)

Is Sorare Just DFS Now?

SorareData Podcast

Play Episode Listen Later Jun 16, 2025 83:44

With the recent Sorare 26 gameplay changes, many managers are asking: Is Sorare now just another daily fantasy game? In this live stream, we compare Sorare to major DFS platforms like DraftKings, FanDuel, and FanTeam — breaking down the similarities, differences, and what the future of fantasy might look like.We'll cover:✅ What DFS really means✅ How Sorare competitions now resemble (or differ from) DFS contests✅ What makes Sorare's card economy and game model unique✅ Why some managers are excited…and others are leavingWhether you're a longtime Sorare player or just exploring fantasy football, this conversation will help you make sense of the changes.

draftkings fanduel dfs sorare fanteam

Travelers Championship Betting & DFS Preview

Inside Golf Podcast

Play Episode Listen Later Jun 15, 2025 73:02

In this episode of the Inside Golf Podcast, The podcast kicks off with an in-depth breakdown of the US Open at Oakmont. Andy reflects on the performances of top players like Bryson DeChambeau, Rory McIlroy, and Scotty Scheffler, analyzing their strengths and misses. He provides a comprehensive preview of the upcoming Travelers Championship at TPC River Highlands, highlighting what attributes are critical for success at this course, including wedge play, putting, and accuracy off the tee. The episode also delves into some significant surprises, mistakes, and wins from recent tournaments, with emphasis on finding the best DFS picks and betting recommendations.BECOME AN INSIDER TODAY: https://www.insidesportsnetwork.com/becomeaninsider Subscribe to the Newsletter: https://inside-sports-network.beehiiv.com/subscribe join Betsperts Golf, with code INSIDEGOLF for 25% off: https://betspertsgolf.com/ Shorties Golf - Use Promo Code ISN15 at checkout https://golfshorties.com/ISN15

Best Ball Strategy, Favorite Builds + An Intervention - Fantasy Football DFS & Betting

Fantasy Footballers DFS - Fantasy Football Podcast

Play Episode Listen Later Jun 13, 2025 69:14

Best Ball draft tips on today's Fantasy Footballers DFS & Betting podcast! Borg & Betz answer listener questions including which strategies work in best ball, favorite builds, and intervene about player exposure rates. Welcome to “DFS and Sports Betting For The Rest of Us.” Take your DFS and Betting Fantasy Football game to the next level on DraftKings, FanDuel, and Underdog Fantasy. -- Fantasy Football Podcast for June 13th, 2025.Best Ball Rankings available in the 2025 UDK+ at UltimateDraftKit.comConnect with The Fantasy Footballers:Visit us on the WebSupport the ShowFollow on XFollow on InstagramJoin our DiscordLove the show? Leave us a review wherever you listen

fantasy football builds betting intervention draftkings fanduel dfs best ball underdog fantasy fantasy football podcasts best ball strategy udk

DFS Has Surgery

Laker Film Room - Dedicated to the Study of Lakers Basketball

Play Episode Listen Later Jun 13, 2025 33:53

Pete and Darius discuss Dorian Finney-Smith's decision to have ankle surgery, what it means that it came at this point in the offseason, how it might impact the free agency decision of his player option, and more. And then later, the guys discuss DFS' role on this roster as a culture setter and locker room presence, how he played this past season, and what they hope to see from him next year on both sides of the ball. Support Pete here: Patreon: https://www.patreon.com/lakerfilmroom Buy Me a Coffee: https://buymeacoffee.com/lakerfilmroom Pete's YouTube: https://www.youtube.com/@LakerFilmRoom Pete's Playback: https://www.playback.tv/lakerfilmroom For Feedback or Questions: lakerfilmroom@gmail.com To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

coffee surgery dfs playback

UFL Championship Preview, Picks & DFS | The UFL Gambling Podcast (Ep. 48)

Play Episode Listen Later Jun 13, 2025 51:12

The UFL Gambling Podcast (@UFLGamblingPod) on the Sports Gambling Podcast Network releases its UFL Championship Preview, Picks & DFS episode.Join the UFL Gambling Podcast for an in-depth preview of the UFL Championship game, including expert insights and DFS picks. The hosts bicker over the matchups, discuss key players, and share their predictions for the game. Tune in for lively debates, humorous tangents, and all the best bets for the big game. Don't miss out on their final thoughts, potential MVP picks, and a special shoutout to the enthusiastic fans behind the scenes.00:00 Intro01:14 Championship Game Excitement01:47 Meet the Hosts03:13 Championship Game Analysis05:57 Betting Props and Predictions22:19 DFS Lineup and Final Thoughts25:10 Quarterback Dilemma: Perkins vs. Tamu25:51 Michigan's Secondary and Offensive Strategy27:07 Running Back Choices and Game Theory28:09 Wide Receiver Stacks and Bargain Picks31:09 Final Lineup Adjustments and MVP Predictions45:41 Attendance Predictions and League Integrity Exclusive SGPN Bonuses And Linkshttp://linktr.ee/sportsgamblingpodcastFollow The Sports Gambling Podcast X/Twitter - https://x.com/GamblingPodcastInstagram - https://www.instagram.com/sportsgamblingpodcastTikTok - https://www.tiktok.com/@gamblingpodcastFacebook - http://www.facebook.com/sportsgamblingpodcastFollow The Sports Gambling Podcast HostsSean Green - http://www.twitter.com/seantgreenRyan Kramer - http://www.twitter.com/kramercentricGambling problem? Call 1-800-GAMBLER CO, DC, IL, IN, LA, MD, MS, NJ, OH, PA, TN, VA, WV, WY Call 877-8-HOPENY or text HOPENY (467369) (NY) Call 1-800-327-5050 (MA)21+ to wager. Please Gamble Responsibly. Call 1-800-NEXT-STEP (AZ), 1-800-522-4700 (KS, NV), 1-800 BETS-OFF (IA), 1-800-270-7117 for confidential help (MI)

ms michigan dc md va mvp tn secondary ks nv wv championship preview dfs hopeny bets off ia next step az gambling podcast ny call gambler co

Minicamp News: What Stories Actually Matter For Rankings (Episode 871 with Evan Silva and Adam Levitan)

Play Episode Listen Later Jun 12, 2025 53:31

Adam Levitan and Evan Silva break down all the news across the NFL as teams conduct their mandatory OTAs and give their insight into the news that could have huge implications on the fantasy football world.In this episode, we discuss:- Can Aaron Rodgers' and Arthur Smith's philosophies coexist? - Is it time to be excited about Christian McCaffrey again?- How J.K. Dobbins fits into the Broncos backfield- Should we still be cautious about Stefon Diggs' injury recovery?- Adam and Evan remember a “big” ETR favoriteTimestamps:0:00 - Intro2:15 - J.K. Dobbins Signs Broncos Deal7:39 - Steelers Sign Aaron Rodgers12:17 - Anthony Richardson Aggravates AC Spain, Out Until Camp16:12 - Christian McCaffrey Full Participation in OTAs19:22 - Nick Chubb Agrees Deal with Texans22:01 - Stefon Diggs Full Go at Patriots OTA24:55 - Brandon Aiyuk Could Start Year on PUP28:10 - Pickett, Flacco Share Starters Reps in Browns OTA29:57 - Luther Burden Misses OTAs with Soft Tissue Injury32:47 - Amon-Ra Undergoes Knee Surgery, Frank Ragnow Retires35:48 - James Cook Holding-In at Bills OTAs36:55 - Terry McLaurin, Commanders Far From New Deal38:53 - Quintin Johnston Expects to be Chargers Starter40:45 - Justin Herbert In Line For More Run Game Usage41:43 - Jaguars Dismiss Travis Etienne Trade Rumours44:22 - Jets Dismiss Breece Hall Trade Rumours, Listed as Starter46:25 - Cowboys Juggle Javonte Williams, Miles Sanders Starting Reps49:26 - Tommy Tremble Undergoes Back Surgery51:04 - Adam's Eulogy for Donald Parham's Torn AchillesDownload the DraftKings Daily Fantasy app now to draft your $20 Best Ball lineup to play for a share of $15 million—and get a second ticket to play FREE for a share of $15 million. That's two chances to win big without ever setting your lineup again. Draft One, Get One—only on DraftKings. The Crown Is Yours. https://dkng.co/BestBallETRGambling Problem? Call 1-800-GAMBLER or 877-8-HOPENY/text HOPENY (467369) (NY). Help is available for problem gambling. Call ⁠(888) 789-7777⁠ or visit ⁠ccpg.org⁠ (CT). 18+ in most eligible states, but age varies by jurisdiction. Eligibility restrictions apply. Void where prohibited. One per customer. Enter the Best Ball $15M headliner contest by 9/4/25 to get one bonus entry. $20 entry fee required. Reward expires in thirty days. See terms at draftkings.com/nfl-best-ball. Sponsored by DK.Want ETR on your team this season? Our 2025 NFL Best Ball Product has you covered with:Real-Time RankingsResearch & Analysis ArticlesDraft Strategy ContentDraft LivestreamsDiscord CommunityQ&As with ETR TeamSubscribe now at https://establishtherun.com/subscribe/ DFS OPTIMIZER: Sign up for THE SOLVER for access to the software we think fantasy players need to win: https://thesolver.com/?ref=etrWE CAN HELP: Tired of attention-seeking hot takes? Get the highest-quality fantasy football analysis in your inbox, FREE: https://bit.ly/establishtherunSPORTSBOOK OFFERS: We've partnered with several major sportsbook outlets to help supply you with the best offers in the industry and ensure you're maximizing your bankroll from the start: https://establishtherun.com/offers/FOLLOW US: Check out our social media channels for FREE fantasy football & DFS videos, analysis, and more: https://linktr.ee/establishtherun

CFL Week 2 Preview, Picks & DFS | The CFL Gambling Podcast (EP. 90)

Play Episode Listen Later Jun 12, 2025 61:22

Join hosts Colby Dant and Justin Mark as they dive into week two of the CFL season with previews, picks, DFS strategies, and huge parlay bets. Featuring insights on the latest team news, player performances, and betting trends, this episode offers detailed analyses of all the upcoming games, key players to watch, and the best bets to make.The hosts also share their thoughts on Vernon Adams, Dedrick Mills, and the questionable performance of the Toronto Argonauts. Don't miss their famous 'Huge Tits Parlay' of the week and all the exciting updates on the CFL Gambling Podcast. Exclusive SGPN Bonuses And Linkshttp://linktr.ee/sportsgamblingpodcastFollow The Sports Gambling Podcast X/Twitter - https://x.com/GamblingPodcastInstagram - https://www.instagram.com/sportsgamblingpodcastTikTok - https://www.tiktok.com/@gamblingpodcastFacebook - http://www.facebook.com/sportsgamblingpodcastFollow The Sports Gambling Podcast HostsSean Green - http://www.twitter.com/seantgreenRyan Kramer - http://www.twitter.com/kramercentricGambling problem? Call 1-800-GAMBLER CO, DC, IL, IN, LA, MD, MS, NJ, OH, PA, TN, VA, WV, WY Call 877-8-HOPENY or text HOPENY (467369) (NY) Call 1-800-327-5050 (MA)21+ to wager. Please Gamble Responsibly. Call 1-800-NEXT-STEP (AZ), 1-800-522-4700 (KS, NV), 1-800 BETS-OFF (IA), 1-800-270-7117 for confidential help (MI)

ms dc md va tn ks nv cfl wv dfs hopeny bets off ia next step az toronto argonauts gambling podcast ny call cfl week vernon adams gambler co dedrick mills

US Open Golf 2025 DraftKings Picks & Lineups | Final Bets, Weather, One & Done Picks

Pat Mayo Experience

Play Episode Listen Later Jun 11, 2025 106:22

Pat Mayo and Tyler Tamboline discuss their favorite 2025 US Open Golf Bets, DFS picks, debate the best roster construction for the week and project ownership for DFS guaranteed prize pools (GPPs). Plus, they review the DFS Ownership and pivot plays. Use code “MAYO” at underdog for a deposit match up to $1000:Get 20% off https://www.fantasynational.com/mayo with code “MAYO” Win a golf trip to Cabot Links at Coolbet: https://shorturl.at/4Ckgd. “SPORTS200” to get a bonus $200 tooDEGEN75 GO FUND ME : https://x.com/ToeTagginTambo/status/1927471560866054146 Travelers Championship — For tickets and information visit TravelersChampionship.com. The Travelers Championship, there is only one! June 18th through the 22ndOMAHA STEAKS — Go to https://OmahaSteaks.com to shop delicious Father's Day gift packages. And use Promo Code MAYO at checkout for an extra $35 off. Minimum purchase may apply. See site for details. A big thanks to our advertiser, Omaha Steaks!HELIX - Go to helixsleep.com/MAYO for 20% OFF SitewideSKIMS — Shop SKIMS Mens at https://www.skims.com/patmayo #skimspartnerCORNBREAD HEMP — save 30% on their first order! Just head to cornbreadhemp.com/PATMAYO and use code PATMAYO at checkout.PXG — Head over to PXG.com/patmayo to save up to 20% on your entire order. Subscribe, Rate and ReviewApple: http://bit.ly/PMEiTunesSpotify: https://goo.gl/VboemH FOLLOW MAYO MEDIA NETWORKNewsletter: https://mayomedia.substack.com/Instagram: https://www.instagram.com/mayomedianetwork/TIK TOK: https://www.tiktok.com/discover/mayo-media-networkYOUTUBE: https://bit.ly/YTMMN SHOW INDEX00:00 Intro3:41 Slate Overview9:27 Weather15:26 Bets45:01 OAD51:22 Underdog1:00:02 DK Ownership1:12:51 DK Lineups1:34:02 Q&A Message and data rates apply. Must be 18+ (21+MA & AZ, 19+ AL, NE) and present in a state where Underdog Fantasy operates. Terms apply. Concerned with your play? Call 1-800-GAMBLER or visit www.ncpgambling.org; AZ: 1-800-NEXT-STEP (1-800-639-8783) or text NEXT-STEP to 53342; NY: Call the 24/7 HOPEline at 1-877-8-HOPENY or Text HOPENY (467369)

Mavs Fantasy Reset & Game 3 Finals Picks